1240 related articles for article (PubMed ID: 29971628)
1. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
2. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Bircan HA; Gurbuz N; Pataer A; Caner A; Kahraman N; Bayraktar E; Bayraktar R; Erdogan MA; Kabil N; Ozpolat B
Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
[TBL] [Abstract][Full Text] [Related]
3. Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3.
Ünal TD; Hamurcu Z; Delibaşı N; Çınar V; Güler A; Gökçe S; Nurdinov N; Ozpolat B
Anticancer Agents Med Chem; 2021; 21(3):355-364. PubMed ID: 32767958
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
5. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
Tekedereli I; Alpay SN; Tavares CD; Cobanoglu ZE; Kaoud TS; Sahin I; Sood AK; Lopez-Berestein G; Dalby KN; Ozpolat B
PLoS One; 2012; 7(7):e41171. PubMed ID: 22911754
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
7. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer.
Shahbazi R; Asik E; Kahraman N; Turk M; Ozpolat B; Ulubayram K
Nanomedicine (Lond); 2017 Aug; 12(16):1961-1973. PubMed ID: 28745127
[TBL] [Abstract][Full Text] [Related]
8. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
Ashour AA; Gurbuz N; Alpay SN; Abdel-Aziz AA; Mansour AM; Huo L; Ozpolat B
J Cell Mol Med; 2014 Nov; 18(11):2235-51. PubMed ID: 25215932
[TBL] [Abstract][Full Text] [Related]
9. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
10. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
11. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
12. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone Alterations of the Apoptotic Gene Expressions and Cell Cycle Arrest in Genetically Distinct Triple-Negative Breast Cancer Cells.
Adinew GM; Messeha SS; Taka E; Badisa RB; Antonie LM; Soliman KFA
Nutrients; 2022 May; 14(10):. PubMed ID: 35631261
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
15. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.
Guan Y; Jiang S; Ye W; Ren X; Wang X; Zhang Y; Yin M; Wang K; Tao Y; Yang J; Cao D; Cheng Y
Cell Death Dis; 2020 Nov; 11(11):948. PubMed ID: 33144562
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
19. TQFL12, a novel synthetic derivative of TQ, inhibits triple-negative breast cancer metastasis and invasion through activating AMPK/ACC pathway.
Wei C; Zou H; Xiao T; Liu X; Wang Q; Cheng J; Fu S; Peng J; Xie X; Fu J
J Cell Mol Med; 2021 Nov; 25(21):10101-10110. PubMed ID: 34609056
[TBL] [Abstract][Full Text] [Related]
20. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
Şakalar Ç; İzgi K; İskender B; Sezen S; Aksu H; Çakır M; Kurt B; Turan A; Canatan H
Tumour Biol; 2016 Apr; 37(4):4467-77. PubMed ID: 26500095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
